- Tytuł:
- 73 - Updated Results of Cartitude-2: Ciltacabtagene Autoleucel (cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor T Cell (CAR-T) Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma (MM) after 1–3 Prior Lines of Therapy
- Autorzy:
- Źródło:
- In Transplantation and Cellular Therapy March 2022 28(3) Supplement:S62-S63
Czasopismo naukowe